GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valbiotis SA (XPAR:ALVAL) » Definitions » LT-Debt-to-Total-Asset

Valbiotis (XPAR:ALVAL) LT-Debt-to-Total-Asset : 0.14 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Valbiotis LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Valbiotis's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.14.

Valbiotis's long-term debt to total assets ratio declined from Dec. 2022 (0.21) to Dec. 2023 (0.14). It may suggest that Valbiotis is progressively becoming less dependent on debt to grow their business.


Valbiotis LT-Debt-to-Total-Asset Historical Data

The historical data trend for Valbiotis's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valbiotis LT-Debt-to-Total-Asset Chart

Valbiotis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.25 0.24 0.22 0.21 0.14

Valbiotis Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.21 0.22 0.14 -

Valbiotis LT-Debt-to-Total-Asset Calculation

Valbiotis's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=4.773/33.309
=0.14

Valbiotis's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=4.773/33.309
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valbiotis  (XPAR:ALVAL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Valbiotis LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Valbiotis's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Valbiotis Business Description

Traded in Other Exchanges
Address
12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of major metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.

Valbiotis Headlines

No Headlines